Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedAaiPharma Inc
BT Catalyst, Feb, 2002
- Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »
> AaiPharma Inc. (Nasdaq: AAII) of Wilmington recently enrolled and dosed the first group of patients in its pivotal Phase III clinical trials for ProSorb(R)-D (diclofenac) pain product, which had promising results in recent Phase II/III studies for analgesic activity. In addition to other positive data in those Phase II/III studies, 72 percent of the patients given ProSorb(R)-D after the removal of impacted molars rated the medication as a very good or excellent pain reliever after a six-hour period.
COPYRIGHT 2002 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning
Find Research Guides for:
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »